Trastuzumab Vedotin
drugOn this page
Also known as Mrg 002MRG-002Mrg002Trastuzumab vedotinaTrastuzumab vedotineTrastuzumab--vcmmae conjugate
Summary
Trastuzumab Vedotin (CHEMBL5315030) is a phase-3 clinical-stage antibody drug conjugate; indicated across 5 conditions including urothelial carcinoma and neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody drug conjugate
- Indications: 5 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315030 |
| Name | Trastuzumab Vedotin |
| Type | Antibody drug conjugate |
| Max phase | 3 |
Also known as: Mrg 002, MRG-002, Mrg002, Trastuzumab vedotin, Trastuzumab vedotina, Trastuzumab vedotine, Trastuzumab–vcmmae conjugate, TRASTUZUMAB VEDOTIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| urothelial carcinoma | 3 | MONDO:0040679 | EFO:0008528 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 6 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05754853 | PHASE3 | RECRUITING | A Study of MRG002 Versus Investigator’s Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer |
| NCT04924699 | PHASE2/PHASE3 | UNKNOWN | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer |
| NCT04492488 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer |
| NCT04742153 | PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) |
| NCT04837508 | PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
| NCT04839510 | PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
| NCT05141747 | PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. |
| NCT05141786 | PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). |
| NCT05263869 | PHASE2 | UNKNOWN | A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients |
| NCT05338957 | PHASE1/PHASE2 | UNKNOWN | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
| NCT04941339 | PHASE1 | UNKNOWN | A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: urothelial carcinoma